Andrew Lancaster, MD
Endocrinology, Diabetes & Metabolism · Alamogordo, NMNPI 1992842934
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $4,048 of the $5,819 with a category attached, or 69.6%. 23 manufacturers reported payments, led by Medtronic at 30.0% of the total.
Across 138 payments — averaging $42.17 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Medtronic$2K
- Tandem Diabetes Care, Inc.$870
- Amgen$623
- Insulet Corporation$399
- Sanofi-aventis U.S. LLC$314
- Xeris Pharmaceuticals, Inc.$283
- plus $2K from 17 others
What the payments were for
- Travel & lodging$1,77230%
- Food & beverage$4,04870%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Medtronic(2 entities) | 20 | $1,744 |
| Tandem Diabetes Care, Inc. | 8 | $870 |
| Amgen(2 entities) | 22 | $623 |
| Insulet Corporation | 13 | $399 |
| Sanofi-aventis U.S. LLC | 16 | $314 |
| Xeris Pharmaceuticals, Inc. | 7 | $283 |
| Lilly USA, LLC | 13 | $272 |
| BETA Bionics, Inc. | 2 | $203 |
| Novo Nordisk | 8 | $194 |
| Neurocrine Biosciences, Inc. | 1 | $139 |
| Radius Health, Inc. | 2 | $117 |
| Bayer | 2 | $116 |
| Abbott | 6 | $113 |
| Inspire Medical Systems, Inc. | 1 | $109 |
| Merck | 4 | $62 |
| Dexcom, Inc. | 1 | $58 |
| AstraZeneca(2 entities) | 4 | $57 |
| Ultragenyx Pharmaceutical Inc. | 2 | $39 |
| Boehringer Ingelheim | 2 | $32 |
| Otsuka America Pharmaceutical, Inc. | 1 | $23 |
| Amryt Pharma Holdings Ltd | 1 | $18 |
| Fresenius USA Marketing, Inc. | 1 | $18 |
| GE HealthCare | 1 | $17 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- MINIMED 780G$1,292
- t-slim insulin pump$771
- iLet Bionic Pancreas$458
- CRENESSITY$139
- EVENITY$127
- Prolia$127
- TEPEZZA$125
- RECORLEV$113
- Omnipod$112
- Inspire$109
- TZIELD$107
- Tymlos$101
- Kerendia$100
How this compares
$5,819 in reported general payments places this provider in the 80th percentile of 42 endocrinology, diabetes & metabolism providers in New Mexico.
See all endocrinology, diabetes & metabolism providers in New Mexico →
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| ForteoTeriparatide | 41 | $182,759 |
| OzempicSemaglutide | 120 | $162,938 |
| TrulicityDulaglutide | 90 | $141,067 |
| JardianceEmpagliflozin | 110 | $129,979 |
| MounjaroTirzepatide | 93 | $123,896 |
| Omnipod 5 Dexg7g6 Pods (Gen 5)Insulin Pump Cart,auto,bt,g6/7 | 46 | $62,308 |
| Humulin R U-500 KwikpenInsulin Regular, Human | 17 | $57,410 |
| FarxigaDapagliflozin Propanediol | 39 | $43,959 |
| Soliqua 100-33Insulin Glargine/Lixisenatide | 23 | $34,217 |
| Humalog Kwikpen U-100Insulin Lispro | 88 | $32,735 |
| Lantus SolostarInsulin Glargine,hum.Rec.Anlog | 167 | $29,367 |
| Tresiba Flextouch U-100Insulin Degludec | 50 | $29,280 |
| Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog | 38 | $26,460 |
| Fiasp FlextouchInsulin Aspart (Niacinamide) | 22 | $22,545 |
| HumalogInsulin Lispro | 60 | $17,730 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Lilly USA, LLCForteo, Trulicity, Mounjaro, Humalog, Insulin Lispro | $272 | $467,560303 claims |
| Novo NordiskOzempic, Novolog, Levemir | $194 | $173,232159 claims |
| Boehringer IngelheimJardiance, Tradjenta | $32 | $145,662125 claims |
| AstraZenecaFarxiga | $57 | $43,95939 claims |
| Sanofi-aventis U.S. LLCSoliqua 100-33, Lantus | $314 | $36,89942 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 42 endocrinology, diabetes & metabolism providers in New Mexico.
Other endocrinology, diabetes & metabolism in Alamogordo
- Robert FerraroAlbuquerque$101K
- Rina Patel TrujilloAlbuquerque$100K
- Jeremy GleesonAlbuquerque$46K
- David SchadeAlbuquerque$16K
- Mansi MehtaAlbuquerque$15K
- Matthew BouchonvilleAlbuquerque$7K
- Teodor DuroAlbuquerque$6K
- Ivan PinonAlbuquerque$5K
- Chukwudi MuojiejeLas Cruces$5K
- Aparimita LahiriLos Alamos$5K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.